0000000000352919

AUTHOR

Marco Stramba-badiale

0000-0001-5900-811x

showing 6 related works from this author

Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.

2014

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these…

Malemedicine.medical_specialtyPhysiologyHypercholesterolemiaLow density lipoprotein cholesterolBlood Pressurelaw.inventionCognitionRandomized controlled triallawRecurrenceInternal medicineblood pressure cognitive decline low-density lipoprotein cholesterol primary prevention secondary prevention strokeInternal MedicineSecondary PreventionMedicineHumansCognitive declineStrokeBeneficial effectsRandomized Controlled Trials as TopicSecondary preventionbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECholesterol LDLmedicine.diseasePrimary PreventionStrokeBlood pressureCholesterolCardiologyPhysical therapylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessStroke incidenceCognition Disordersblood pressure; cognitive decline; low-density lipoprotein cholesterol; primary prevention; secondary prevention; strokeJournal of hypertension
researchProduct

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive tre…

2016

medicine.medical_specialtyPhysiologybusiness.industry030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineBlood pressureSprintShot (pellet)Internal MedicinePhysical therapyMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessStrokeJournal of hypertension
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the Euro…

2014

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive pati…

Malemedicine.medical_specialtyChinaPhysiologyBlood Pressurelaw.inventionchemistry.chemical_compoundCognitionRandomized controlled triallawRecurrenceInternal medicineInternal MedicinemedicineSecondary Preventionblood pressure; cognitive decline; low-density lipoprotein cholesterol; randomized controlled trial; secondary prevention; strokeDementiaHumansProspective StudiesCognitive declineProspective cohort studyStrokeAntihypertensive AgentsAgedLdl cholesterolCholesterolbusiness.industryBlood Pressure DeterminationCholesterol LDLlipoprotein cholesterol randomized controlled trial secondary prevention strokeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseblood pressure cognitive decline low-densityEuropeStrokeBlood pressurechemistryIschemic Attack TransientHypertensionPhysical therapyCardiologyDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessCognition Disorders
researchProduct

An Immersive Motor Protocol for Frailty Rehabilitation

2019

Frailty is a pre-clinical condition that worsens physical health and quality of life. One of the most frequent symptoms of frailty is an increased risk of falling. In order to reduce this risk, we propose an innovative virtual reality motor rehabilitation program based on an immersive tool. All exercises will take place in the CAVE, a four-screen room with a stationary bike. The protocol will include two types of exercises for the improvement of balance: “Positive Bike” and “Avoid the Rocks.” We will choose evaluation scales related to the functional aspects and subjective perception of balance. Our aim is to prove that our innovative motor rehabilitation protocol is as effective as or more…

psychometricsmedicine.medical_specialtymedicine.medical_treatmentfrailtyVirtual realityelderlylcsh:RC346-429CAVE; balance; elderly; frailty; motor rehabilitation; risk of falls; stationary bike; virtual reality03 medical and health sciencesstationary bike0302 clinical medicineQuality of life (healthcare)Physical medicine and rehabilitationStationary bikemedicineSettore M-PSI/01 - PSICOLOGIA GENERALEbook.short_story030212 general & internal medicinebookProtocol (object-oriented programming)lcsh:Neurology. Diseases of the nervous systemBalance (ability)computational psychometricsBalance; CAVE; Elderly; Frailty; Motor rehabilitation; Risk of falls; Stationary bike; Virtual realityRehabilitationrisk of fallsCAVEbalancemotor rehabilitation3. Good healthMotor rehabilitationIncreased riskNeurologyPerspectivevirtual realityNeurology (clinical)Psychology030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Usability issues of clinical and research applications of virtual reality in older people: A systematic review

2020

Aging is a condition that may be characterized by a decline in physical, sensory, and mental capacities, while increased morbidity and multimorbidity may be associated with disability. A wide range of clinical conditions (e.g., frailty, mild cognitive impairment, metabolic syndrome) and age-related diseases (e.g., Alzheimer's and Parkinson's disease, cancer, sarcopenia, cardiovascular and respiratory diseases) affect older people. Virtual reality (VR) is a novel and promising tool for assessment and rehabilitation in older people. Usability is a crucial factor that must be considered when designing virtual systems for medicine. We conducted a systematic review with Preferred Reporting Items…

Agingmedicine.medical_treatmentApplied psychologyUsabilityContext (language use)DiseaseVirtual realityAssessmentAffect (psychology)050105 experimental psychologyVirtual realitylcsh:RC321-57103 medical and health sciencesBehavioral Neuroscience0302 clinical medicineUser experience designmedicineSettore M-PSI/01 - PSICOLOGIA GENERALE0501 psychology and cognitive scienceslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryRehabilitationbusiness.industry05 social sciencesRehabilitationUsabilityHuman NeuroscienceUser-experiencePsychiatry and Mental healthNeuropsychology and Physiological PsychologySystematic reviewNeurologySystematic ReviewbusinessPsychology030217 neurology & neurosurgery
researchProduct